Research programme: Src kinase inhibitors - KeyNeurotek AG
Alternative Names: SRN 004Latest Information Update: 26 Feb 2008
At a glance
- Originator KeyNeurotek AG
- Developer KeyNeurotek Pharmaceuticals AG
- Class Small molecules
- Mechanism of Action Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Jul 2004 Preclinical trials in Cancer in Germany (unspecified route)